|
Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL).
- Previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy.
More Info about Zevalin
| Drug Type: | Cancer |
| Current FDA Status: | Approved |
| Current Drug Phase: | Market |
|